Selected Posters and Abstracts
Abacavir (Ziagen)
•[P101] Once-daily (QD) abacavir (ABC)/lamivudine (3TC) and ritonavir-boosted atazanavir (ATV/r) in antiretroviral naïve HIV-1infected subjects: 24-week analysis from COL102060 (SHARE)
R Elion and others.
•[P219A] Outcomes of antiretroviral regimens containing Abacavir (ABC) with Tenofovir (TDF) in treatment-experienced patients: predictors of response and drug resistance evolution in failing patients
S Di Giambenedetto and others.
•[P150] Comparison of efficacy and toxicity profile of abacavir (ABA) and tenofovir (TDF) containing regimens
C Smith and others.
•[P16] ABC/3TC in combination with a boosted PI in clinical practice
A Carganico and others.
•[P117] Value of the HLAB*5701 allele to predict abacavir hypersensitivity in Spaniards
S Rodriguez-Novoa and others.
•[P115] Abacavir hypersensitivity reaction in EuroSIDA
W Bannister and others.
•[PL9.2] HLA-B5701 testing and abacavir hypersensitivity: a single centre experience
L Waters and others.
•[P114] Abacavir-associated drug hypersensitivity is strongly associated with the human leukocyte antigen B-57 allele
N Tesch and others.
•[P50] Study of changes in CD4 cells count after switching tenofovir to abacavir or TDF and didanosine to ABC+lamivudine in patients with a ddI+TDF containing regimen and viral suppression (Europa study): preliminary analysis
E Pedrol and others.
•[P116] Screening for HLA B5701 in a population of HIV patients of diverse ethnic origin exposed to abacavir in France
D Zucman and others.
•[P216] Genotypic resistance in HIV+ naive patients enrolled in a 96-week randomized trial comparing abacavir (ABC) vs. stavudine (d4T), both combined with lamivudine/efavirenz (3TC/EFV)
E Ferrer and others.
•

[P170] Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and satisfaction with therapy
D Maitland and others.

 

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada